Skip to content
DemonstrationReset
Sign up
Your account
Reg CFTRL98.8–9.0Tier IIFully committed

Vantage Isotopes

Vantage Isotopes Revenue Share

A share of metered output from an operating actinium-225 and molybdenum-99 production line.

Actinium-225 is one of the scarcest useful substances on earth and targeted alpha therapy demand is growing faster than supply. Vantage operates an accelerator-driven subcritical target that has been shipping for two years under three take-or-pay distribution agreements. Investors receive 4% of gross isotope revenue until a 1.9x cap, paid quarterly against metered output.

Discovery Ridge Research Park · Columbia, MOIn commercial operationEscrow: Cadence Escrow Services
TRL 9 of 9, band 8.8 to 9, signed by Dr. Samuel Adeyemi, PhD Nuclear Engineering; ASME Section III reviewer, on May 15, 2026.See the evidence it rests on

$5,000,000 committed of $5,000,000

$5,000,000 released · 100% subscribed

Released to the issuerCommitted, held in escrowRemaining
Minimum
$100

$50 per unit

Instrument
Revenue share
Term
10 yr
Investors
2,766

Closed April 30, 2026

Sign in to see your limit

  • Eligibility depends on residency, accreditation status and how much you have already invested this year.
  • You can read everything about this offering without an account. Committing capital requires one.
Open an account
Open an account to invest

Demo · viewing as

Browsing without an account. Everything is visible; nothing is purchasable until you verify who and where you are.

Or answer the questions yourself

No money will move

No payment processor is connected. The commitment flow runs end to end, through amount, agreement, signature and receipt, and records a simulated position rather than a charge.

Use of proceeds

  • 51%Second production target station
  • 27%Hot cell and processing capacity
  • 14%Distribution and cold chain
  • 8%Offering expenses and platform fees

The issuer

Accelerator-driven subcritical production of molybdenum-99 and actinium-225 for diagnostic imaging and targeted alpha therapy. Operating and shipping.

Legal name
Vantage Isotopes, LLC
Entity
Delaware LLC
Jurisdiction
Missouri
Founded
2017

  • Sofia MarchettiChief Executive Officer

    Radiopharmaceutical supply chain, formerly head of isotope operations at a research reactor facility.